A brain-permeable inhibitor of the neurodegenerative disease target kynurenine 3-monooxygenase prevents accumulation of neurotoxic metabolites
Year: 2019
Type: article
Abstract: Dysregulation of the kynurenine pathway (KP) leads to imbalances in neuroactive metabolites associated with the pathogenesis of several neurodegenerative disorders, including Huntington’s disease (HD). Inhibition of the enzyme kynurenine 3-monooxygenase (KMO) in the KP normalises these metabolic imbalances and ameliorates neurodegeneration and related phenotypes in several neurodegenerative disease models. KMO is thus a promising candidate drug target for these disorders, but known inhibitors are not brain permeable. Here, 19 new KMO inhibitors have been identified. One of these ( 1 ) is neuroprotective in a Drosophila HD model but is minimally brain penetrant in mice. The prodrug variant ( 1b ) crosses the blood–brain barrier, releases 1 in the brain, thereby lowering levels of 3-hydroxykynurenine, a toxic KP metabolite linked to neurodegeneration. Prodrug 1b will advance development of targeted therapies against multiple neurodegenerative and neuroinflammatory diseases in which KP likely plays a role, including HD, Alzheimer’s disease, and Parkinson’s disease.
Source: Communications Biology
Authors: Shaowei Zhang, Michiyo Sakuma, Girdhar S. Deora, Colin W. Levy, Alex Klausing, Carlo Breda, Kevin D. Read, Chris D. Edlin, Benjamin P. Ross, Marina Wright Muelas, Philip J. Day, Stephen O’Hagan, Douglas B. Kell, Robert Schwarcz, David Leys, Derren J. Heyes, Flaviano Giorgini, Nigel S. Scrutton
Language: English
Subfield: Biological Psychiatry
Field: Neuroscience
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $3,170
Funders: U.S. Department of Health and Human Services, Diamond Light Source, Research Councils UK, University of Leicester, Directorate for Biological Sciences, Medical Research Council, Engineering and Physical Sciences Research Council, Biotechnology and Biological Sciences Research Council, National Institute of Mental Health
Awards: The roles of transporters in the human metabolic network, Catalysis in motion: accessing how fast motions facilitate catalysis through pump-probe and fast time resolved spectroscopies., CENTRE FOR SYNTHETIC BIOLOGY OF FINE AND SPECIALITY CHEMICALS, CHARACTERISING KYNURENINE 3-MONOOXYGENASE (KMO) AS A THERAPEUTIC TARGET FOR HUNTINGTON'S DISEASE, G3573154115, Kynurenic Acid and Cognitive Abnormalities in Schizophrenia, G3791971324, G6117159763, G700842229, Future Biomanufacturing Research Hub, G7500235039, The roles of transporters in the human metabolic network, MultiUSer equipment for high-throughput, high-content analysis in Industrial and Cellular biotechnology (MUSIC)
OpenAlex ID: W2954416791
